Horizon Heralds Stellar Launch Of TED Drug Tepezza
One Of The Best New Product Launches In Years
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
You may also be interested in...
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).
Horizon Pharma is on track to file its top pipeline asset for regulatory approval this year after its Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease met primary and secondary endpoints.